The training session on WHO and national guidelines for hepatitis C prevention and control was held in Jianyang, Sichuan province on Nov 15, 2019. This session was co-sponsored by China Liver Health and the People’s Hospital of Jianyang City. 153 first-line healthcare workers from departments of infectious diseases, liver disease, digestive diseases and laboratory medicine in 37 hospitals in Jianyang and surrounding cities and counties participated in the training.
Group photo of guests Secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC, deputy division chief Li Yongchun from the Health Commission of Sichuan Province, director Huang Anwen from the Health Commission of Jianyang, director Li Mingyang from China Liver Health, Prof. Tang Hong, Prof. Bai Lang, Prof. Chen Enqiang, Prof. Li Hong, Prof. Wang Dongmei from West China Hospital of Sichuan University, Prof. He Qinying from the Chengdu Center for Disease Control and Prevention, Prof. Yang Li from the People’s Hospital of Jianyang City and other experts attended the meeting. Deputy division chief Li Yongchun from the Health Commission of Sichuan Province and director Huang Anwen from the Health Commission of Jianyang delivered a speech. Vice president Xu Wenge from the People's Hospital of Jianyang City gave a welcome speech. The training session was co-chaired by director Mao Yurong from the division of hepatitis C/STD prevention and treatment, National Center for AIDS/STD Control and Prevention under China CDC, and Prof. Fu Wanzhi.
At the training session This event is one of the series of activities in the China Hepatitis C Elimination Alliance Public Welfare Project, with academician Zhuang Hui, a foremost authority on hepatology, serving as the general counsel. Nearly 1360 healthcare workers have taken part in the training in Chengdu of Sichuan province, Hefei of Anhui province, Tianjin, Wuwei of Gansu province, Xining of Qinghai province, Zunyi of Guizhou province, Baoshan of Yunnan province and other places. Based on WHO and national guidelines for hepatitis C prevention and control, the project aims to implement the National Viral Hepatitis Prevention and Control Plan (2017-2020) and promote the integration of national hepatitis C screening and management standard with international standards so as to improve the cure rate of hepatitis C and strengthen management of adverse reactions.
Viral hepatitis C (referred to as hepatitis C) is a blood-borne and sexually transmitted disease which can progress to severe diseases such as liver fibrosis, cirrhosis, and liver cancer, causing serious disease burden to the society and families. Hepatitis C can be completely cured with oral direct-acting antivirals (DAAs). In China, there are 10 million people infected with hepatitis C virus. However, due to the insidious onset, insufficient attention from patients, high costs of drugs and other reasons, most of them have not been detected and effectively treated.
Deputy division chief Li Yongchun from the Health Commission of Sichuan Province delivered a speech.
Director Huang Anwen from the Health Commission of Jianyang delivered a speech.
Vice president Xu Wenge from the People's Hospital of Jianyang City delivered a speech.
Director Mao Yurong from the division of hepatitis C/STD prevention and treatment, National Center for AIDS/STD Control and Prevention under China CDC, presided over the meeting.
Prof. Fu Wanzhi presided over the meeting. In the speech, deputy division chief Li Yongchun from the Health Commission of Sichuan Province and director Huang Anwen from the Health Commission of Jianyang expressed gratitude to liver disease experts for their efforts in eliminating hepatitis. Eliminating hepatitis C is one of the major tasks in implementing Healthy China 2030 initiative. By actively integrating social resources to jointly promote hepatitis C screening, detection, prevention and treatment, China Hepatitis C Elimination Alliance Public Welfare Project will be an effective attempt for infectious disease prevention and control.
Director Li Mingyang from China Liver Health announced the Decision on Awarding the People’s Hospital of Jianyang the Base Hospital of China Hepatitis C Elimination Alliance Public Welfare Project and, together with Prof. Tang Hong from West China Hospital, conferred the plaque to vice president Xu Wenge and Prof. Fu Wanzhi.
Awarding ceremony for the People’s Hospital of Jianyang Secretary Liu Zhongfu from the National Center for AIDS/STD Control and Prevention under China CDC interpreted the epidemic situation, prevention and control strategy of hepatitis C in China. There are about 10 million people infected with hepatitis C virus (HCV) domestically. According to the Global Health Sector Strategy (GHSS) on Viral Hepatitis adopted by the World Health Assembly, China should achieve the goal of 90% of HCV infections being diagnosed and 80% of confirmed cases being treated by 2030. In terms of this goal, healthcare workers in China still have a long way to go.
Secretary Liu Zhongfu introduced the epidemic status and prevention and control progress of hepatitis in China.
Prof. Tanghong interpreted the WHO guideline on hepatitis C prevention and control.
Prof. He Qinying from the Chengdu Center for Disease Control and Prevention introduced Chengdu Implementation Plan for Eliminating Hepatitis C Prof. Tang Hong from the West China Hospital of Sichuan University systematically interpreted the WHO guideline on hepatitis C prevention and control. Prof. He Qinying, director of the Chengdu Center for Disease Control and Prevention, introduced the implementation plan and work progress in eliminating hepatitis C in Chengdu. Prof. Li Hong, Prof. Chen Enqiang and Prof. Bai Lang from the West China Hospital respectively discussed how to easily and effectively clear HCV, the progress in diagnosis and treatment of chronic hepatitis B and the clinical application of an artificial liver support system, double plasma molecular adsorption system (DPMAS). Prof. Wang Dongmei from Chengdu Public Health Clinical Medical Center introduced laboratory diagnostic methods for tuberculosis and its application. Prof. Yang Li from the People's Hospital of Jianyang City reviewed the diagnosis progress of liver fibrosis and fatty liver. Zhu Xiuguang, director of social responsibility department of Beijing Easy to Raise Network Technology Co., Ltd, introduced how the people living in extreme poverty can get assistance for critical illness on the internet public fundraising information platform designated by the Ministry of Civil Affairs.
Prof. Li Hong from West China Hospital of Sichuan University
Prof. Chen Enqiang from West China Hospital of Sichuan University
Prof. Bai Lang from West China Hospital of Sichuan University
Prof. Wang Dongmei from Chengdu Public Health Clinical Medical Center
Prof. Yang Li from the People’s Hospital of Jianyang City
Zhu Xiuguang, director of social responsibility department of Beijing Easy to Raise Network Technology Co., Ltd
Director Li Mingyang introduced the China Hepatitis C Elimination Alliance Public Welfare Project. Director Li Mingyang from China Liver Health said that, under the guidance of Health Commission of Jianyang, the China Hepatitis C Elimination Alliance Public Welfare Project would carry out in-depth cooperation with local hospitals, provide supports for primary health care institutions to carry out health education for hepatitis C prevention and control in communities, provide help in the detection and diagnosis of high-risk groups so as to contribute to hepatitis C elimination in Jianyang. As a supporting measure, China Liver Health is promoting the incorporation of online donation into the hepatitis C elimination work system, guiding and assisting patients in extreme financial difficulties to apply for major disease relief so as to get social charity funds and reduce the incidence of impoverishment caused by disease.
[Background Information] Viral hepatitis C (referred to as hepatitis C) is a blood-borne and sexually transmitted disease which can progress to severe diseases such as liver fibrosis, cirrhosis, and liver cancer, causing serious disease burden to the society and families. Hepatitis C can be completely cured with oral direct-acting antivirals (DAAs). In Ch |
关注官方微信 
